/ /

  • linkedin
  • Increase Font
  • Sharebar

    New IOL, automated delivery system expected to transform market

    Alcon Laboratories received CE Mark approval in July 2017 for its new monofocal hydrophobic acrylic intraocular lenses (IOL), called Clareon. Three months later, the company’s disposable, automated delivery system preloaded with the Clareon IOL (AutonoMe) gained the CE Mark. Both the Clareon IOL and the AutonoMe delivery system are being called market innovations.

    The Clareon IOL is constructed of a novel hydrophobic acrylic material and has the benefit of reduced potential for glistening development.

    The Clareon IOL is constructed of a novel, patented hydrophobic acrylic material that maintains the desirable performance characteristics appreciated by surgeons using AcrySof IOLs (Alcon) and has the benefit of reduced potential for glistening development.

    The AutonoMe incorporates a carbon dioxide-powered delivery mechanism, was designed for ease of use, and gives surgeons precise control over IOL insertion.

    “The AutonoMe delivery system is the first and only disposable, automated, preloaded delivery system in the world,” explained Stephen S. Lane, MD, chief medical officer, Alcon, Fort Worth, TX. “It will change the way in which surgeons deliver IOLs into the eye. It is easy and intuitive to use and allows for predictable delivery of a truly pristine premium IOL that is made of a new hydrophobic biomaterial with unsurpassed clarity.”

    The lens and delivery system have received the CE Mark and were launched at the 2017 European Society of Cataract and Refractive Surgeons meeting. The lens and delivery system are not yet approved in the United States.


    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results